News & Information
At Memorial Sloan Kettering, our leading edge research is constantly advancing what we know about cancer and new discoveries are improving care for patients here, and all over the world. In News and Information, you will find information about our groundbreaking work and the dedicated professionals who make it all happen.
For Journalists
Connect with us to reach MSK experts for media inquiries and for story ideas.
Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since these prestigious rankings were established more than 30 years ago, MSK has consistently ranked among the top two cancer hospitals in the country.
For more than 137 years, MSK has made historic contributions driving discovery and improving patient care. Take a look back at the progress we've made since the signing of the National Cancer Act in 1971.
In the News
Rectal cancer patients saw their tumors disappear in a clinical trial involving immunotherapy at Memorial Sloan Kettering Cancer Center—without surgery, radiation, or chemotherapy.
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.
Stay Connected with MSK
News Releases
Memorial Sloan Kettering Cancer Center (MSK) today announced that Selwyn M. Vickers, MD, FACS, an internationally recognized pancreatic cancer surgeon and researcher, a pioneer in cancer health disparities research, and an academic medical leader, has been selected to serve as its next President and Chief Executive Officer.
Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. This new approach of “immunoablative” therapy uses immunotherapy to replace surgery, chemotherapy and radiation to remove cancer.
New data from researchers at MSK featured in the 2022 ASCO Annual Meeting press program and simultaneously published in The New England Journal of Medicine highlights a novel antibody-drug conjugate that doubled progression-free survival in HER2-low metastatic breast cancer.
Media Coverage
There’s a strong business case to be made for reaching diverse talent. But there’s much more at stake than just the bottom line. MSK’s Selwyn Vickers is featured.
Friday, September 2, 2022
Many guys love a breakfast plate piled high with sausages and maybe a sugar-glazed danish on the side. Now, research shows that wolfing down too many ultra-processed foods like these could be bad news for a man’s colon. MSK’s Robin Mendelsohn is quoted.
Friday, September 2, 2022
Memorial Sloan Kettering (MSK) Cancer Centre has launched its facility in Chennai to provide patients diagnosed with cancer an access to the institute’s oncologists. MSK’s Mrinal M. Gounder is featured.
Monday, August 29, 2022
News from the Lab
The revised scoring system incorporates molecular information related to 31 genes to help predict risk.
Called NEXT, the factor plays an important role in handing over RNA to the exosome for destruction.
By detecting molecular signatures in the blood, the sensor may help improve cancer screenings.
MSK News
Symantha Wilson was crushed when chemotherapy quit fighting her lymphoma — and thrilled when immuno¬therapy beat back the cancer. But why doesn’t immunotherapy help more people? MSK researchers are finding answers.
This new era of cancer research investigates how the disease in certain locations interacts with all the body’s systems. Focusing on cancer’s ecosystem promises to reveal lifesaving insights, especially into metastasis.
To help Bridget Anderson overcome leukemia, MSK doctors called upon her own microbiome, the vast ecosystem of microorganisms that live within us, especially the gut. They’re both friend and foe in fighting cancer.
2021 Annual Report: Bold Discovery. Life-Changing Care.
A new approach that selectively seeks out and destroys prostate cancer cells represents a major leap forward for treating men with the disease.
People of color suffer heartbreaking disparities in cancer outcomes. MSK is determined to help in every facet of cancer care, from lifesaving research to better access to the world’s best treatment.
To develop better immunotherapies for cancer, SKI tumor immunologist Andrea Schietinger is seeking inspiration from an unlikely source: autoimmune diseases.
